These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 16542049)

  • 21. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
    Takada I; Makishima M
    Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety issues and prospects for future generations of PPAR modulators.
    Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
    Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists.
    Benz V; Kintscher U; Foryst-Ludwig A
    Handb Exp Pharmacol; 2012; (214):387-410. PubMed ID: 23027460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Libby P; Plutzky J
    Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
    Pershadsingh HA
    Int J Biochem Cell Biol; 2006; 38(5-6):766-81. PubMed ID: 16298156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [PPAR family and its relationship to metabolic syndrome].
    Zhang XY; Chen LH; Guan YF
    Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):6-12. PubMed ID: 15881336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The next generation of PPAR drugs: do we have the tools to find them?
    Shearer BG; Billin AN
    Biochim Biophys Acta; 2007 Aug; 1771(8):1082-93. PubMed ID: 17602866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P; Rose M; Singh M
    Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
    Ahmed I; Furlong K; Flood J; Treat VP; Goldstein BJ
    Am J Ther; 2007; 14(1):49-62. PubMed ID: 17303976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and evaluation of new 1,2,4-oxadiazole based trans- acrylic acid derivatives as potential PPAR-alpha/gamma dual agonist.
    Kaur P; Bhat ZR; Bhat S; Kumar R; Kumar R; Tikoo K; Gupta J; Khurana N; Kaur J; Khatik GL
    Bioorg Chem; 2020 Jul; 100():103867. PubMed ID: 32353564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach.
    D'Aniello E; Fellous T; Iannotti FA; Gentile A; Allarà M; Balestrieri F; Gray R; Amodeo P; Vitale RM; Di Marzo V
    Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):586-597. PubMed ID: 30611848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development].
    Duran-Sandoval D; Thomas AC; Bailleul B; Fruchart JC; Staels B
    Med Sci (Paris); 2003; 19(8-9):819-25. PubMed ID: 14593612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new insight into the treatment of diabetes by means of pan PPAR agonists.
    Chandra A; Kaur P; Sahu SK; Mittal A
    Chem Biol Drug Des; 2022 Dec; 100(6):947-967. PubMed ID: 34990085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
    Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of peroxisome proliferator activated receptors (PPAR)-γ and -α agonists on cochlear protection from oxidative stress.
    Sekulic-Jablanovic M; Petkovic V; Wright MB; Kucharava K; Huerzeler N; Levano S; Brand Y; Leitmeyer K; Glutz A; Bausch A; Bodmer D
    PLoS One; 2017; 12(11):e0188596. PubMed ID: 29182629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
    Kasai S; Inoue T; Yoshitomi H; Hihara T; Matsuura F; Harada H; Shinoda M; Tanaka I
    J Pharmacol Sci; 2008 Sep; 108(1):40-8. PubMed ID: 18776709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.
    Azhar S
    Future Cardiol; 2010 Sep; 6(5):657-91. PubMed ID: 20932114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
    Matin A; Gavande N; Kim MS; Yang NX; Salam NK; Hanrahan JR; Roubin RH; Hibbs DE
    J Med Chem; 2009 Nov; 52(21):6835-50. PubMed ID: 19807106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.